Price
$32.13
Decreased by -1.74%
Dollar Volume
12.90 M
ADR%
6.02
Market Cap.
1.46 B
Shares Float
25.41 M
Shares Outstanding
43.85 M
Beta
0.00
Price / Earnings
-2.07
BPR
798.59
20D Range
28.35 35.23
50D Range
18.71 35.23
200D Range
6.04 35.23
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 14, 22 -2.12 -0.89
Decreased by -138.20%
Aug 15, 22 -0.88 -1.07
Increased by +17.76%
May 12, 22 -1.56 -0.64
Decreased by -143.75%
Mar 24, 22 -39.85 -0.66
Decreased by -5.94 K%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
-92.87 M
Decreased by -921.38%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00 - -32.09 M -
Decreased by N/A%
-
Mar 31, 22 0.00 - -32.38 M -
Decreased by N/A%
-
Dec 31, 21 0.00 - -64.97 M -
Decreased by N/A%
-
Dec 31, 20 0.00 - -9.09 M -
Decreased by N/A%
-
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. It has strategic alliance with Kite to co-develop and co-commercialize CART-ddBCMA. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.